OTCMKTS:GSGTF GenSight Biologics (GSGTF) Stock Price, News & Analysis $0.24 0.00 (0.00%) As of 05/9/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About GenSight Biologics Stock (OTCMKTS:GSGTF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GenSight Biologics alerts:Sign Up Key Stats Today's Range$0.24▼$0.2450-Day Range$0.24▼$0.2452-Week Range$0.32▼$0.32VolumeN/AAverage Volume583 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.Read More… Receive GSGTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GenSight Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address GSGTF Stock News HeadlinesGenSight Biologics SA (G49N) Gets a Hold from Kepler CapitalApril 10, 2025 | markets.businessinsider.comGenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business UpdateApril 7, 2025 | businesswire.comTrump to redistribute trillions of dollars What’s most shocking about this list for me is stock #2. It’s primed to be the biggest beneficiary of the DOGE administration’s efforts to eradicate the filth and corruption plaguing our government. But the thing is… it’s actually not an Elon stock.May 10, 2025 | Porter & Company (Ad)Kepler Capital Keeps Their Hold Rating on GenSight Biologics SA (G49N)March 22, 2025 | markets.businessinsider.comGenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with EstimatesMarch 19, 2025 | businesswire.comGenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025March 17, 2025 | finance.yahoo.comGenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025March 17, 2025 | businesswire.comKepler Capital Remains a Hold on GenSight Biologics SA (G49N)March 1, 2025 | markets.businessinsider.comSee More Headlines GSGTF Stock Analysis - Frequently Asked Questions How have GSGTF shares performed this year? GenSight Biologics' stock was trading at $0.24 on January 1st, 2025. Since then, GSGTF shares have increased by 0.0% and is now trading at $0.24. View the best growth stocks for 2025 here. How do I buy shares of GenSight Biologics? Shares of GSGTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:GSGTF CIKN/A Webwww.gensight-biologics.com Phone(317) 621-7220FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (OTCMKTS:GSGTF) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThis robot is coming to 65 million Americans … this year.The Robotics Revolution has arrived. And not surprisingly, Nvidia is leading the way. Nvidia CEO Jensen ...Weiss Ratings | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew breed of trader (Wall Street hates us?)Wall Street big wigs and old-money bankers can’t touch this 1 type of stock. And that opens the door for tr...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredYou Were Looted.While you were saving and investing the right way… they were rewriting the rules behind closed doors. Now 5...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GenSight Biologics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share GenSight Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.